Friday 26 February 2021

Dooda Covid-19 Miracle Cure ISN’T

The UK is now less than four weeks away from an anniversary that few will celebrate with any relish: the 23rd of next month marks a year since alleged Prime Minister Alexander Boris de Pfeffel Johnson appeared on TV and solemnly instructed the country “You must stay home”. Now that we are on the third period of Covid-19 restrictions, some out there are proving highly susceptible to those peddling miracle cures.


So it was that self-promoting TalkRADIO host Julia Hartley Brewer read an article in the Daily Mail, failed to perform the most basic checks upon its veracity, and told her adoring audience “Ivermectin, a drug used to treat lice and scabies drug [sic], could cut Covid deaths by up to 75%, new research suggests. What are we waiting for?

Sadly for Ms Hartley Dooda, this appears to be yet another example of people seeing something that looks too good to be true - because it is too good to be true. So let’s start at the very beginning, as it’s a very good place to start, with the Mail’s supposed exposé.


A cheap and safe drug widely used against parasites cuts Covid infections, hospitalisations and deaths by about 75 per cent, a study shows. More than 30 trials across the world found that ivermectin causes ‘repeated, consistent, large magnitude improvements in clinical outcomes’ at all stages of the disease”. Do go on.

The peer-reviewed study, to be published in the US journal Frontiers of Pharmacology, says the evidence is so strong that the drug - used to treat head lice and scabies - should become a standard therapy everywhere, so hastening the global recovery”. And, as Fred Flintstone might have said, hold it … HOLD IT!


A search for “Frontiers of Pharmacology” returns, er, no results at all. This, presumably, is a reference to Frontiers IN Pharmacology, one of many Frontiers series titles. Wikipedia tells us thatFrontiers journals have a controversial reputation”, and, indeed, devotes a whole section of its entry for Frontiers Journals to “Controversies”, including this gem: “As of 2013, the overall rejection rate was 20% of all submitted manuscripts, compared to the top-tier, paywalled Nature journal, which rejected 90% of them”.

And this is what Merck, a former patent holder for the drug, said earlier this month. “Company scientists continue to carefully examine the findings of all available and emerging studies of ivermectin for the treatment of COVID-19 for evidence of efficacy and safety. It is important to note that, to-date, our analysis has identified: No scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies; No meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease, and; A concerning lack of safety data in the majority of studies”.


There was more. “We do not believe that the data available support the safety and efficacy of ivermectin beyond the doses and populations indicated in the regulatory agency-approved prescribing information”. Which does NOT include prescribing ivermectin for treatment of Covid-19. David Rose, who penned the Mail article, could have found that out in a few minutes. So could Ms Hartley Dooda. That’s a most unfortunate omission.

The KBF wackos and other denialists will lap this up. For everyone else, there’s reality.


Enjoy your visit to Zelo Street? You can help this truly independent blog carry on talking truth to power, while retaining its sense of humour, by adding to its Just Giving page at

https://www.justgiving.com/crowdfunding/zelostreet8

7 comments:

  1. A quick search on David Rose, the author of the Mail piece, reveals that he is a not altogether uncontroversial figure or a particularly reliable author.

    His Wikipedia entry reveals him to be a climate change denier, has been censured by IPSO and the author of two defamatory articles in the Mail on Sunday.

    ReplyDelete
  2. "Despite this negative result, there seemed to be a tendency to reduce viral load and an early recovery from hyposmia/anosmia in the treated group. Adverse events were not statistically significant, and authors suggest evaluating ivermectin for early COVID-19 treatment and as pre-exposure prophylaxis in high-risk groups."
    https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00024-9/fulltext

    Meanwhile Merck continue to try and gain entry into the vaccine manufacturing business.

    ReplyDelete
  3. In the case of Brewer, Grimes , Young et al I would recommend an alternative anti parasite medication. A Novichok enema.

    ReplyDelete
  4. Do Rothermere, mister and missus Dooda or any of their relatives, "friends" or acquaintances own shares in said Ivermectin manufacturing company?

    ReplyDelete
  5. pooper-scooper really is the pits

    ReplyDelete
  6. Will Dooda come forward as a guneia pig or will the vaccine reject the host as being too bitter and full of resentment to work?

    ReplyDelete
  7. @Steve Woods

    He's been covered here many times https://zelo-street.blogspot.com/search?q=david+rose

    ReplyDelete